Prevail raises big money for Parkinson’s | March 19, 2018 Issue - Vol. 96 Issue 12 | Chemical & Engineering News
Volume 96 Issue 12 | p. 13 | Concentrates
Issue Date: March 19, 2018

Prevail raises big money for Parkinson’s

By Ryan Cross
Department: Business
Keywords: Gene therapy, Prevail Therapeutics, AAV, Parkinson's, AAV9, Regenxbio, NYC

In another impressive first round of funding for a New York City biotech firm, Prevail Therapeutics has raised a $75 million series A. Prevail launched with seed funding last year to develop adeno-associated virus (AAV)-based gene therapies for neurodegenerative diseases related to lysosomal dysfunction, including a subset of Parkinson’s disease. Prevail will use Regenxbio’s AAV9 vector, which targets the nervous system.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment